TY - JOUR
T1 - Nonalcoholic Fatty Liver Disease
T2 - An Underrecognized Cause of Cryptogenic Cirrhosis
AU - Clark, Jeanne M.
AU - Diehl, Anna Mae
PY - 2003/6/11
Y1 - 2003/6/11
N2 - Cryptogenic cirrhosis is a common cause of liver-related morbidity and mortality in the United States. Nonalcoholic fatty liver disease (NAFLD) is now recognized as the most common cause of cryptogenic cirrhosis. However, the diagnosis of cirrhosis in patients with NAFLD appears to be delayed compared with those with other chronic liver diseases and thus carries a higher mortality rate. This delay in diagnosis is illustrated in our case of a 53-year-old man who presented with hepatic hydrothorax and ascites, whose workup revealed cirrhosis due to NAFLD. Although a diagnosis of presumed NAFLD can be made noninvasively, a definitive diagnosis requires a liver biopsy specimen. A biopsy specimen is also important for detecting histologically advanced disease, which may be clinically silent and undetected by amino-transferases or diagnostic imaging. Although there are no proven treatments, recommendations for patients with NAFLD include avoidance of hepatotoxins and aggressive management of associated conditions, such as hypertriglyceridemia and type 2 diabetes mellitus.
AB - Cryptogenic cirrhosis is a common cause of liver-related morbidity and mortality in the United States. Nonalcoholic fatty liver disease (NAFLD) is now recognized as the most common cause of cryptogenic cirrhosis. However, the diagnosis of cirrhosis in patients with NAFLD appears to be delayed compared with those with other chronic liver diseases and thus carries a higher mortality rate. This delay in diagnosis is illustrated in our case of a 53-year-old man who presented with hepatic hydrothorax and ascites, whose workup revealed cirrhosis due to NAFLD. Although a diagnosis of presumed NAFLD can be made noninvasively, a definitive diagnosis requires a liver biopsy specimen. A biopsy specimen is also important for detecting histologically advanced disease, which may be clinically silent and undetected by amino-transferases or diagnostic imaging. Although there are no proven treatments, recommendations for patients with NAFLD include avoidance of hepatotoxins and aggressive management of associated conditions, such as hypertriglyceridemia and type 2 diabetes mellitus.
UR - http://www.scopus.com/inward/record.url?scp=0038142845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038142845&partnerID=8YFLogxK
U2 - 10.1001/jama.289.22.3000
DO - 10.1001/jama.289.22.3000
M3 - Article
C2 - 12799409
AN - SCOPUS:0038142845
SN - 0098-7484
VL - 289
SP - 3000
EP - 3004
JO - JAMA
JF - JAMA
IS - 22
ER -